Janus Henderson Group Ltd. filed an amended Schedule 13G reporting beneficial ownership of common stock of Vaxcyte, Inc.. Through its asset management subsidiaries acting on behalf of client accounts (Managed Portfolios), Janus Henderson may be deemed to beneficially own 65,694 shares of Vaxcyte common stock, representing 0.1% of the class.
The filing states that Janus Henderson has no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over 65,694 shares via its Asset Managers. The Managed Portfolios, not Janus Henderson, have the right to receive all dividends and sale proceeds, and none of the individual Managed Portfolios own more than five percent of Vaxcyte’s common stock.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned:65,694 sharesPercent of class:0.1%Shared voting power:65,694 shares+3 more
6 metrics
Shares beneficially owned65,694 sharesCommon stock of Vaxcyte, Inc. beneficially owned through Asset Managers
Percent of class0.1%Portion of Vaxcyte common stock class attributed to Janus Henderson
Shared voting power65,694 sharesShares over which Janus Henderson has shared power to vote or direct the vote
Shared dispositive power65,694 sharesShares over which Janus Henderson has shared power to dispose or direct disposition
Sole voting power0 sharesShares over which Janus Henderson has sole power to vote or direct the vote
Sole dispositive power0 sharesShares over which Janus Henderson has sole power to dispose or direct disposition
"the Asset Managers may be deemed to be the beneficial owner of 65,694 common stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting powerfinancial
"Shared Voting Power 65,694.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 65,694.00"
Managed Portfoliosfinancial
"collectively referred to herein as Managed Portfolios"
parent holding companyfinancial
"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"
What percentage of Vaxcyte (PCVX) shares does Janus Henderson Group report owning?
Janus Henderson Group Ltd. reports beneficial ownership of 0.1% of Vaxcyte’s common stock, corresponding to 65,694 shares. This ownership is held through various asset management subsidiaries on behalf of client Managed Portfolios.
How many Vaxcyte (PCVX) shares are reported as beneficially owned by Janus Henderson?
Janus Henderson may be deemed to beneficially own 65,694 shares of Vaxcyte common stock. These shares are held in client Managed Portfolios for which its asset management subsidiaries exercise investment and/or voting discretion.
Does Janus Henderson have sole or shared voting power over its Vaxcyte (PCVX) holdings?
Janus Henderson reports 0 shares with sole voting power and 65,694 shares with shared voting power in Vaxcyte. Voting authority is exercised by its asset management subsidiaries on behalf of client Managed Portfolios.
Who receives dividends and sale proceeds from the Vaxcyte (PCVX) shares managed by Janus Henderson?
The Managed Portfolios receive all dividends and sale proceeds from the Vaxcyte shares. Janus Henderson and its Asset Managers disclaim ownership of dividend or sale rights associated with these securities.
Do any Janus Henderson Managed Portfolios own more than 5% of Vaxcyte (PCVX) stock?
No. The filing states that none of the Managed Portfolios own more than five percent of Vaxcyte, Inc. common stock, even though their aggregated holdings total 65,694 shares, or 0.1% of the class.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 10)
VAXCYTE, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
92243G108
(CUSIP Number)
07/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92243G108
1
Names of Reporting Persons
JANUS HENDERSON GROUP Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
JERSEY
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
65,694.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
65,694.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
65,694.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
VAXCYTE, INC.
(b)
Address of issuer's principal executive offices:
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA 94070
Item 2.
(a)
Name of person filing:
Janus Henderson Group Ltd.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Janus Henderson Group Ltd. It does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.s ultimate parent Jupiter Topco LLC, the direct or indirect owners of Jupiter Topco LLC, or other persons that may be deemed under control of such owners. Any beneficial ownership by such persons has been disaggregated from that of Janus Henderson Group Ltd. in accordance with the release.
(b)
Address or principal business office or, if none, residence:
201 Bishopsgate
EC2M 3AE, United Kingdom
(c)
Citizenship:
Y9
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
92243G108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, Victory Park Capital Advisors LLC, and Richard Berstein Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 65,694 common stock of Vaxcyte, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)
Percent of class:
0.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
65694
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
65694
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts.
Of the Managed Portfolios, none own more than five percent of the common stock of Vaxcyte, Inc.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Please refer to Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
N/A
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
N/A
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
